Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
MSD Japan Spins Off Organon Women’s Health Biz, Ryota Sakurai Takes Helm
In tandem with its global spinoff, the Japan arm of US Merck split off its Organon women’s health and legacy brand business on June 3, with Ryota Sakurai, who has been spearheading the transition, taking up the role of president…
To read the full story
Related Article
- Organon CMO Calls for Balance between Innovation and Access to Longer-Listed Drugs
March 19, 2025
- Organon Japan to Focus on Women’s Health, Enrich Offerings with Global Products: President
June 29, 2021
- MSD Japan Suffers 7% Sales Dip on Repeated Keytruda Re-Pricing, Urges Policy Rethink
April 21, 2021
- MSD Japan to Get Women’s Health Spinoff Organon Up and Running in October: Chief
April 7, 2020
- MSD Japan Embarking on 2-Step Spinoff for Women’s Health, Legacy Brands
February 28, 2020
BUSINESS
- Nippon Kayaku’s Avastin Biosimilar Share Hits 58%
February 3, 2026
- Japan’s 1st OTC Morning-After Pill Now Available
February 3, 2026
- Amgen Ends Rocatinlimab Pact with Kyowa Kirin
February 3, 2026
- AstraZeneca Names Andy Barnett as New Japan President
February 3, 2026
- Shionogi Eyes Faster QOL Biz Expansion with Ex-JT Researchers: CEO
February 2, 2026
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…